Teleflex (TFX) Receives Daily News Impact Score of 0.08

News stories about Teleflex (NYSE:TFX) have trended somewhat positive recently, according to Accern. The research firm scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Teleflex earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave media headlines about the medical technology company an impact score of 47.1614514730351 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Several brokerages recently issued reports on TFX. ValuEngine lowered shares of Teleflex from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Jefferies Group boosted their target price on shares of Teleflex from $270.00 to $295.00 and gave the company a “buy” rating in a research report on Friday, November 3rd. Morgan Stanley boosted their target price on shares of Teleflex from $274.00 to $290.00 and gave the company an “equal weight” rating in a research report on Friday, November 3rd. Piper Jaffray Companies began coverage on shares of Teleflex in a research report on Friday, November 10th. They set an “overweight” rating and a $295.00 target price for the company. Finally, Deutsche Bank lowered shares of Teleflex from a “buy” rating to a “hold” rating and set a $251.00 target price for the company. in a research report on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $274.44.

Teleflex (NYSE TFX) traded down $0.48 during trading on Friday, reaching $249.44. 150,434 shares of the company were exchanged, compared to its average volume of 316,151. The stock has a market capitalization of $11,258.71, a P/E ratio of 45.52, a price-to-earnings-growth ratio of 2.14 and a beta of 1.09. The company has a current ratio of 4.72, a quick ratio of 3.70 and a debt-to-equity ratio of 0.88. Teleflex has a 52 week low of $157.80 and a 52 week high of $271.23.

Teleflex (NYSE:TFX) last released its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.01 by $0.11. Teleflex had a net margin of 12.41% and a return on equity of 16.27%. The company had revenue of $534.70 million for the quarter, compared to the consensus estimate of $522.94 million. During the same quarter in the prior year, the firm earned $1.80 earnings per share. Teleflex’s revenue was up 17.3% on a year-over-year basis. sell-side analysts anticipate that Teleflex will post 8.35 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, December 15th. Stockholders of record on Wednesday, November 15th were issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.55%. The ex-dividend date was Tuesday, November 14th. Teleflex’s payout ratio is presently 24.82%.

In other Teleflex news, CEO Benson Smith sold 2,000 shares of the stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $258.10, for a total transaction of $516,200.00. Following the transaction, the chief executive officer now directly owns 76,634 shares in the company, valued at approximately $19,779,235.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $265.32, for a total transaction of $53,064.00. Following the transaction, the director now owns 8,080 shares in the company, valued at $2,143,785.60. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,600 shares of company stock worth $665,076. Company insiders own 2.39% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.com-unik.info/2017/12/24/teleflex-tfx-receives-daily-news-impact-score-of-0-08.html.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Insider Buying and Selling by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit